Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aspirin/lisinopril/lovastatin - CardioPharma

Next Previous
Drug Profile

Aspirin/lisinopril/lovastatin - CardioPharma

Alternative Names: CardiaPill; CP-101; polypill-CardioPharma

Latest Information Update: 05 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CardioPharma
  • Class Acetates; Analgesics; Anti-inflammatories; Antihyperlipidaemics; Antihypertensives; Antineoplastics; Antiplatelets; Antipyretics; Antirheumatics; Benzoic acids; Carboxylic acids; Dipeptides; Esters; Heart failure therapies; Irritable bowel syndrome therapies; Lactones; Naphthalenes; Nonsteroidal anti-inflammatories; Salicylic acids; Small molecules
  • Mechanism of Action ACE inhibitors; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Immunomodulators; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Cardiovascular disorders

Most Recent Events

  • 05 Jan 2026 Aspirin/lisinopril/lovastatin is still in clinical trials for Cardiovascular disorders in USA (CardioPharma pipeline, January 2026)
  • 14 May 2024 CardioPharma files for patent protection for Aspirin/lisinopril/lovastatin in Canada, New Zealand, and Israel, prior to May 2024
  • 14 May 2024 CardioPharma has patent protection for Aspirin/lisinopril/lovastatin in Australia, Armenia, Belarus, and the Russian Federation, prior to May 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top